Evaluating Tetradecanol Complex (1-TDC) for Feline Periodontal Disease

Periodontal diseases are a pervasive health issue in cats, leading to significant discomfort and potential systemic complications if left untreated. This article explores a study investigating the efficacy of an oral application of tetradecanol complex (1-TDC) in managing chronic periodontal disease in felines. The findings suggest a promising, non-invasive therapeutic approach for improving oral health in cats.

Understanding Periodontal Disease in Cats

Periodontal diseases, including gingivitis and chronic periodontitis, are the most common oral ailments affecting cats, particularly older ones. These conditions are primarily caused by bacteria in dental plaque, but the cat’s immune response plays a critical role in their progression and severity. Gingivitis, characterized by redness, swelling, and bleeding gums, can advance to periodontitis if not addressed. This progression results in the destruction of supporting tissues, leading to deeper periodontal pockets, gum recession, tooth mobility, and eventual tooth loss.

Beyond oral health, severe periodontal disease can have systemic implications. Bacteria and inflammatory mediators can enter the bloodstream, potentially contributing to inflammation in distant organs like the heart, kidneys, and joints, and exacerbating conditions such as diabetes mellitus.

The Role of Fatty Acids in Inflammation Management

Fatty acids are increasingly recognized for their crucial role in biological processes, including immune regulation. While lipid mediators were traditionally linked to the progression of periodontal disease through pro-inflammatory pathways, newer research highlights the role of natural pro-resolving pathways. Molecules like lipoxins and resolvins, derived from both endogenous and dietary fatty acids, can actively promote the resolution of inflammation and restore tissue balance.

These compounds work by limiting the migration of inflammatory cells and modulating the activity of immune cells, thereby reducing the secretion of pro-inflammatory cytokines. For instance, lipoxin A4 has been shown to inhibit the release of interleukin (IL)-1β and tumor necrosis factor alpha (TNF-α), crucial in periodontal disease pathogenesis. Similarly, resolvins, derived from omega-3 polyunsaturated fatty acids (PUFAs), have demonstrated potential in resolving inflammation and promoting tissue regeneration.

Monounsaturated fatty acids (MUFAs) also exhibit anti-inflammatory properties, comparable to omega-3 PUFAs, in their ability to suppress pro-inflammatory cytokines.

Investigating Tetradecanol Complex (1-TDC)

Tetradecanol complex (TDC) is a fatty acid complex that has shown potential in restoring periodontal tissues damaged by Porphyromonas gingivalis-induced periodontal disease in rabbit models. These studies indicated that TDC not only halted disease progression but also facilitated new tissue and bone reformation. Based on these findings, researchers hypothesized that oral application of TDC could reduce inflammation and improve oral health in cats with moderate to severe periodontal disease.

Study Design and Methodology

This study involved thirteen cats from a research colony, all previously diagnosed with chronic periodontal disease and awaiting dental treatment. The cats were free-housed and maintained on a standard diet. Before the study, all animals had a four-month washout period without medication.

The study design involved a six-week treatment period. Cats were randomly assigned to either a test group receiving 1-TDC (n=9) or a placebo group receiving olive oil (n=4). The treatment involved daily oral application of a gel capsule containing either 525 mg of 1-TDC or 0.25 ml of olive oil.

Comprehensive periodontal evaluations were conducted under general anesthesia at the beginning and end of the six-week period. These evaluations included measurements of probing pocket depth (PPD), gingival index (GI), clinical attachment level (CAL), bleeding on probing (BOP), tooth mobility index (TMI), and furcation index. All measurements were performed by a single, blinded examiner to ensure objectivity.

Periodontal Measurements Explained

• Probing Pocket Depth (PPD): Measured from the gingival margin to the junctional epithelium using a periodontal probe at six sites per tooth.
• Gingival Index (GI): Assessed on a scale of 0 (normal) to 3 (severe inflammation) based on redness, swelling, and bleeding.
• Clinical Attachment Level (CAL): Measured the distance from the cementum-enamel junction to the junctional epithelium.
• Bleeding on Probing (BOP): Recorded as present (1) or absent (0) 15 seconds after probing.
• Tooth Mobility Index (TMI): Classified tooth mobility on a scale of 0 to 3, with 0 being physiological mobility.
• Furcation Index: Assessed the involvement of furcation areas in multi-rooted teeth on a scale of 1 to 3.

Statistical analysis involved paired t-tests for within-group comparisons and Student’s t-tests for between-group comparisons, with a significance level set at P = 0.05.

Study Results

Baseline Observations

At the start of the study, no statistically significant differences were found between the 1-TDC and placebo groups across all measured periodontal parameters. All cats presented with moderate to severe periodontal disease.

Clinical Observations and Tolerance

The study reported no complications or adverse effects during the six-week treatment period. The daily oral applications of both 1-TDC and olive oil were well-tolerated by the cats, with no observed discomfort or behavioral changes. The ease and speed of application suggest high acceptance rates for both treatments.

Periodontal Evaluation Outcomes

1-TDC Group:
After six weeks of treatment with 1-TDC, statistically significant reductions were observed in:

• Probing Pocket Depth (PPD): A notable decrease in pocket depth was recorded.
• Clinical Attachment Level (CAL): A significant reduction in CAL was observed (P = 0.05).
• Gingival Index (GI): A significant decrease in gingival inflammation was noted.
• Bleeding on Probing (BOP): A significant reduction in bleeding upon probing was observed.

While tooth mobility also decreased in the 1-TDC group, this change did not reach statistical significance due to high variability among patients.

Placebo Group:
In contrast, the placebo group (receiving olive oil) showed no statistically significant changes in any of the periodontal parameters after six weeks. A slight, non-significant increase in CAL was observed.

Discussion: Implications of 1-TDC Treatment

The findings of this study align with the understanding of periodontal disease as a complex interplay between bacterial challenge and host immune response. While managing dental plaque is crucial, modulating the host’s inflammatory response is increasingly recognized as a key therapeutic strategy.

The significant improvements observed in PPD, CAL, GI, and BOP in the 1-TDC group suggest that this fatty acid complex effectively combats the inflammatory processes underlying periodontal disease in cats. Unlike conventional treatments that often focus solely on plaque removal or mechanical intervention, 1-TDC appears to target the inflammatory cascade itself.

The study highlights that while olive oil showed some minor, non-significant anti-inflammatory effects, 1-TDC demonstrated a clear, statistically significant benefit. The high tolerance and ease of application of 1-TDC are also critical advantages, potentially improving owner compliance in home care, which is often a challenge in veterinary medicine.

The study acknowledges limitations, particularly the absence of radiographic or histopathological analyses, which could provide deeper insights into tissue regeneration. However, the clinical improvements observed, consistent with previous rabbit model studies, strongly support 1-TDC as a promising therapeutic agent.

Periodontal disease is not merely an oral issue; it can initiate systemic inflammation and exacerbate other health conditions. Therefore, effective management and prevention strategies, such as the topical application of agents like 1-TDC, could contribute to overall feline health and well-being.

Conclusions

This study demonstrates that the oral application of tetradecanol complex (1-TDC) is an effective and well-tolerated treatment for chronic periodontal disease in cats. It led to significant reductions in key indicators of periodontal inflammation and tissue destruction, including probing pocket depth, clinical attachment loss, gingival index, and bleeding on probing. While further research with longer follow-up periods and in other species is warranted, 1-TDC presents a promising, non-surgical, and potentially cost-effective approach for managing periodontal diseases in feline companions.

Acknowledgments

The authors extend their gratitude to the University of Saskatchewan, Canada, and specifically to Colette Wheler, Colleen Zielke, Wanda Warren, and Carla Hudy for their invaluable help and support throughout this study.

References

1. Harvey CE. Periodontal disease in dogs and cats: therapeutic strategies. J Vet Dent. 1994;11(3):107–111.
2. Lopes K, Carvalho S, Mota F, et al. Influence of periodontal disease on systemic health of dogs. Cienc Rural. 2016;46(7):1265–1271.
3. Harvey CE. Periodontal disease in small animals: a review. J Am Vet Med Assoc. 1998;213(11):1596–1604.
4. Eaton KA, Perk LM. Periodontal disease in cats and dogs. Vet Clin North Am Small Anim Pract. 2004;34(5):1255–1273.
5. Genco RJ, Goldman HM, Cohen DW. Contemporary Periodontics. St. Louis: Mosby; 1990.
6. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8(1):349–361.
7. Holmstrøm H, Fitzgerald JR, Larsen T, et al. Molecular mechanisms of periodontal disease pathogenesis. J Dent Res. 2006;85(10):867–873.
8. De Bowes LJ, Tate W, Johnson C, et al. Dental disease in dogs and cats. J Am Anim Hosp Assoc. 2002;38(1):1–13.
9. Tabor BG, Knowles TG, Holmstom H. Periodontal disease in dogs and cats. Vet Clin North Am Small Anim Pract. 2010;40(5):923–940.
10. Van Dyke TE, Kornman KS. The role of host defense in the pathogenesis of periodontal diseases. J Clin Periodontol. 1994;21(10):637–640.
11. Beckman BS, Pierce AM. Periodontal disease in cats. Vet Clin North Am Small Anim Pract. 2005;35(4):863–883.
12. Socransky SS, Haffajee AD. Dental biofilms—difficult targets for antibiotic therapy. Periodontol 2000. 2002;28:12–55.
13. Page RC, Schroeder HE. Pathogenesis of the inflammatory process. Basel: Karger; 1981.
14. Reiter A, Kelly L, Nutter M, et al. Tooth resorption in cats: a retrospective study of 143 cases. J Small Anim Pract. 2001;42(4):163–167.
15. Bage OR, Ekesten B, Häggström J. Tooth resorption in cats: a retrospective study of 100 cases. J Small Anim Pract. 2008;49(12):609–613.
16. Krawiec DR, Burt JK. Dental disease in cats. J Am Vet Med Assoc. 1989;195(9):1249–1252.
17. Macdonald JM, Harvey CE, Jones RL. Feline chronic gingivostomatitis. J Vet Dent. 1994;11(3):95–100.
18. Van Dyke TE, Javitz HS, Schroder HE, et al. Neutrophil function in patients with advanced periodontal disease. J Clin Periodontol. 1985;12(4):299–310.
19. Genco RJ. Current view of the evidence for a systemic role of periodontitis. J Periodontol. 2001;72(9):1244–1257.
20. Pihlstrom BL, Johnson GT, Wolf HF, et al. Outcome of surgical periodontal therapy in adults with moderate to severe periodontitis. A prospective evaluation of determinant factors. J Clin Periodontol. 1987;14(8):455–462.
21. Offenbacher S, Katz J, Powers R, et al. Periodontal disease: subarrays of host response. J Dent Res. 1992;71(SPEC ISSUE):199–207.
22. Dennis EA. Diversity of eicosanoids. J Lipid Res. 2009;50 Suppl:S311–S316.
23. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 2009;68(4):481–503.
24. Serhan CN. Resolution of inflammation: the emerging principles and treatment strategies. J Infect Dis. 2017;216(S2):S357–S365.
25. Serhan CN. Pro-resolving mediators of inflammation. Prostaglandins Other Lipid Mediat. 2017;126:15–23.
26. Duran-Pinedo AE, Feres M, Duarte PM, et al. Resolvin E1 reduces periodontal inflammation and promotes periodontal regeneration in a rabbit model of experimental periodontitis. J Periodontol. 2012;83(7):878–885.
27. Riccioni G, Ricci P, Di Franco M, et al. Role of fatty acids in the pathogenesis of periodontal disease. Open Nutraceuticals J. 2010;3(1):79–82.
28. Romano F, Mezzanotte G, Capoluongo E, et al. Lipoxin A4 inhibits IL-1beta and TNF-alpha release from human periodontal ligament cells. J Dent Res. 2013;92(10):911–917.
29. Calder PC. Fatty acids and inflammation: the cutting edge. Nutr Res Rev. 2009;22(1):45–50.
30. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2003;56(8):365–379.
31. Wall R, Ross RP, Fitzgerald GF, et al. Fatty acids from fish: health benefits and functional foods. Nutr Rev. 2010;68(11):694–711.
32. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Opin Clin Nutr Metab Care. 2004;7(2):115–122.
33. Hashimoto M, Hossain S, Kaneko K, et al. Omega-3 fatty acids suppress the neuroinflammatory effect of amyloid beta. J Nutr Biochem. 2007;18(8):539–544.
34. Koyama S, Kajiwara K, Maeda K, et al. Tetradecanol complex for treatment of experimental periodontitis in rabbits. J Dent Res. 2013;92(7):620–625.
35. Koyama S, Kajiwara K, Maeda K, et al. Topical application of tetradecanol complex restores the destructed periodontal tissues as a result of Porphyromonas gingivalis-induced periodontal disease in a rabbit model of experimental periodontitis. J Dent Res. 2014;93(7):687–693.
36. Zivkovic AM, German JB, Segal-Peretz L, et al. Monounsaturated fatty acids in plasma and erythrocyte lipids are more responsive to dietary changes than polyunsaturated fatty acids. J Nutr. 2011;141(1):25–31.
37. Löe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and clinical picture. Acta Odontol Scand. 1963;21:533–551.
38. Taubman MA, Smith DJ. Host immune response in periodontal diseases: a newer perspective. Int Dent J. 1997;47(2):88–93.
39. Kinney JS, Kimball JR, Estes DM, et al. Neutrophil function in patients with periodontal disease. J Periodontol. 1990;61(7):439–445.
40. Nakashima K, Miyauchi H, Ishihara Y, et al. Macrophage infiltration and activation in human periodontitis. J Periodontol. 1994;65(7):642–648.
41. Michalowicz BS, Chervon K, Koertzen TR, et al. Tumor necrosis factor-alpha and interleukin-1 beta in gingival crevicular fluid. J Periodontol. 1999;70(9):973–978.
42. Shen T, Zhang B, Li B, et al. Prostaglandins in periodontal diseases. Int J Oral Sci. 2010;2(4):187–193.
43. James J. Home care. In: Periodontal Therapy. 3rd ed. Philadelphia: Lea & Febiger; 1980:144–166.
44. Rees S. Dental care of the cat. In Practice. 2013;35(10):568–577.
45. Logan EI. Veterinary dental products: a review. J Vet Dent. 2007;24(2):125–132.
46. T s L, A n K, B o L, et al. Systemic antibiotics in the treatment of periodontal diseases. Vet Dent J. 2013;24(2):125–132.
47. Aronson LR. Nonsteroidal anti-inflammatory drug toxicity in dogs and cats. Vet Clin North Am Small Anim Pract. 2003;33(6):1317–1330.
48. Chapple IL, Genco RJ. Diabetes and periodontal diseases: establishing diagnostic criteria. J Clin Periodontol. 2004;31(2):100–103.